GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Cyclically Adjusted Book per Share

Hansa Biopharma AB (OSTO:HNSA) Cyclically Adjusted Book per Share : kr13.55 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Hansa Biopharma AB's adjusted book value per share for the three months ended in Mar. 2024 was kr-7.105. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr13.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Hansa Biopharma AB's average Cyclically Adjusted Book Growth Rate was -1.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 13.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Hansa Biopharma AB was 13.90% per year. The lowest was 13.90% per year. And the median was 13.90% per year.

As of today (2024-06-05), Hansa Biopharma AB's current stock price is kr49.66. Hansa Biopharma AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr13.55. Hansa Biopharma AB's Cyclically Adjusted PB Ratio of today is 3.66.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Hansa Biopharma AB was 25.28. The lowest was 1.50. And the median was 4.58.


Hansa Biopharma AB Cyclically Adjusted Book per Share Historical Data

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Cyclically Adjusted Book per Share Chart

Hansa Biopharma AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 9.51 11.41 13.61 14.07

Hansa Biopharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.79 14.05 14.03 14.07 13.55

Competitive Comparison of Hansa Biopharma AB's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted PB Ratio falls into.



Hansa Biopharma AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-7.105/132.2054*132.2054
=-7.105

Current CPI (Mar. 2024) = 132.2054.

Hansa Biopharma AB Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.591 100.432 3.411
201409 0.000 100.161 0.000
201412 1.824 100.225 2.406
201503 1.524 99.950 2.016
201506 7.530 99.995 9.956
201509 7.098 100.228 9.363
201512 6.526 100.276 8.604
201603 5.890 100.751 7.729
201606 4.943 101.019 6.469
201609 4.283 101.138 5.599
201612 8.093 102.022 10.487
201703 6.848 102.022 8.874
201706 5.665 102.752 7.289
201709 4.735 103.279 6.061
201712 16.681 103.793 21.247
201803 15.624 103.962 19.869
201806 14.257 104.875 17.972
201809 13.277 105.679 16.610
201812 21.518 105.912 26.860
201903 20.863 105.886 26.049
201906 18.873 106.742 23.375
201909 16.692 107.214 20.583
201912 14.061 107.766 17.250
202003 11.841 106.563 14.690
202006 9.446 107.498 11.617
202009 30.089 107.635 36.958
202012 27.930 108.296 34.096
202103 25.854 108.360 31.544
202106 23.188 108.928 28.143
202109 20.227 110.338 24.236
202112 17.034 112.486 20.020
202203 14.300 114.825 16.464
202206 10.810 118.384 12.072
202209 7.734 122.296 8.361
202212 11.496 126.365 12.027
202303 7.907 127.042 8.228
202306 3.474 129.407 3.549
202309 -1.186 130.224 -1.204
202312 -3.187 131.912 -3.194
202403 -7.105 132.205 -7.105

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Hansa Biopharma AB  (OSTO:HNSA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Hansa Biopharma AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=49.66/13.55
=3.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Hansa Biopharma AB was 25.28. The lowest was 1.50. And the median was 4.58.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Hansa Biopharma AB Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry
Traded in Other Exchanges
Address
Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines